Back to Search Start Over

Natural immunity against capsular group X N. meningitidis following an outbreak in Togo, 2007

Authors :
Andrew J. Pollard
Tsidi Agbeko Tamekloe
Gunnstein Norheim
Berthe-Marie Njanpop-Lafourcade
Roshan Ramasamy
Ray Borrow
Jerry C. Nagaputra
Lisbeth Meyer Næss
Christine S. Rollier
Hilary Watt
Helen Findlow
Judith E. Mueller
Ouli Xie
Abiba Banla Kere
Christina Dold
Isabelle Delrieu
Norwegian Institute of Public Health [Oslo] (NIPH)
Oxford Vaccine Group
University of Oxford [Oxford]-Oxford NIHR Biomedical Research Centre-The Churchill hospital
École des Hautes Études en Santé Publique [EHESP] (EHESP)
Département Méthodes quantitatives en santé publique (METIS)
Epidémiologie des Maladies Emergentes - Emerging Diseases Epidemiology
Pasteur-Cnam Risques infectieux et émergents (PACRI)
Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] (CNAM)
Agence de Médecine Préventive
Public Health England [London]
Ministry of Health [Togo]
Imperial College London
Institut National d’Hygiene [Togo]
This work was funded by a research grant from the Meningitis Research Foundation, U.K. (Grant number 0906.1) and supported by the Oxford Partnership Comprehensive Biomedical Research Centre with funding from the NIHR Biomedical Research Centre Programme.
University of Oxford-Oxford NIHR Biomedical Research Centre-The Churchill hospital
Institut Pasteur [Paris] (IP)
Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)
HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Institut Pasteur [Paris] (IP)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)
HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)
Source :
Vaccine, Vaccine, Elsevier, 2018, 36 (10), pp.1297-1303. ⟨10.1016/j.vaccine.2018.01.031⟩, Vaccine, 2018, 36 (10), pp.1297-1303. ⟨10.1016/j.vaccine.2018.01.031⟩
Publication Year :
2018
Publisher :
Elsevier, 2018.

Abstract

Background Capsular group X N. meningitidis (MenX) has emerged as a cause of localized disease outbreaks in sub-Saharan Africa, but the human immune response following exposure to MenX antigens is poorly described. We therefore assessed the natural immunity against MenX in individuals who were living in an area affected by a MenX outbreak during 2007 in Togo, West Africa. During 2009, 300 healthy individuals (100 aged 3–5 years, 100 aged 13–19 years and 100 aged 20–25 years) were included in the study, and serum responses were compared with sera from age-matched controls from the U.K. and Burkina Faso. Methods MenX serum bactericidal antibody (SBA) was measured using rabbit complement, and antibodies against MenX polysaccharide (XPS) and outer membrane vesicles (XOMVs) were quantified by ELISA. Results The proportion of Togolese individuals with an SBA titer of ≥8 against the MenX strain was 29% (95% confidence interval (CI) 18–41) among those aged 3–5 years, 34% (95% CI 9–60) among those aged 13–19 years and 32% (95% CI 24–40) among those aged 20–25 years. These were significantly higher than observed in the control populations from the U.K (range 13–16%) and Burkina Faso (range 2–6%). Conclusion In Togolese individuals, the concentration of serum IgG against XPS was higher among the two older age groups as compared to the youngest age group. Antibody concentrations against MenX PS correlated significantly with SBA titers. This supports further development of a MenX PS based conjugate vaccine. Further studies are needed to verify the ability of MenX PS to induce SBA in humans.

Details

Language :
English
ISSN :
0264410X
Database :
OpenAIRE
Journal :
Vaccine, Vaccine, Elsevier, 2018, 36 (10), pp.1297-1303. ⟨10.1016/j.vaccine.2018.01.031⟩, Vaccine, 2018, 36 (10), pp.1297-1303. ⟨10.1016/j.vaccine.2018.01.031⟩
Accession number :
edsair.doi.dedup.....a5e9c6db108195dd0f4810f73d251bad